Imatinib: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 8: | Line 8: | ||
* 2009 Global Sales: $3.9 Billion | * 2009 Global Sales: $3.9 Billion | ||
* Importance: It is one of the best selling [[cancer]] drugs of all time. It was the drug to be approved from the tyrosine kinase inhibitor class of drugs. It is very specific receptor tyrosine kinase (RTK) inhibitor, binding to Abl, PDGFR and KIT with far greater specificity than other RTKs, helping explain its relatively low impact side effect profile. Has generated significant controversy due to its nearly $65,000 per year cost at a time when global health care budgets are being stretched thin.<ref>A Conversation With Brian J. Druker, M.D., Researcher Behind the Drug Gleevec by Claudia Dreifus, The New York Times, November 2, 2009</ref> | * Importance: It is one of the best selling [[cancer]] drugs of all time. It was the drug to be approved from the tyrosine kinase inhibitor class of drugs. It is very specific receptor tyrosine kinase (RTK) inhibitor, binding to Abl, PDGFR and KIT with far greater specificity than other RTKs, helping explain its relatively low impact side effect profile. Has generated significant controversy due to its nearly $65,000 per year cost at a time when global health care budgets are being stretched thin.<ref>A Conversation With Brian J. Druker, M.D., Researcher Behind the Drug Gleevec by Claudia Dreifus, The New York Times, November 2, 2009</ref> | ||
* See also [[Bcr-Abl and Imatinib (STI571 or Gleevec)]] | |||
* See [[Pharmaceutical Drugs]] for more information about other drugs and disorders | * See [[Pharmaceutical Drugs]] for more information about other drugs and disorders | ||
